HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status.

AbstractBACKGROUND:
Poor nutritional status and both hyper- and hypophosphatemia are associated with increased mortality in maintenance hemodialysis (HD) patients. We assessed associations of phosphate binder prescription with survival and indicators of nutritional status in maintenance HD patients.
STUDY DESIGN:
Prospective cohort study (DOPPS [Dialysis Outcomes and Practice Patterns Study]), 1996-2008.
SETTING & PARTICIPANTS:
23,898 maintenance HD patients at 923 facilities in 12 countries.
PREDICTORS:
Patient-level phosphate binder prescription and case-mix-adjusted facility percentage of phosphate binder prescription using an instrumental-variable analysis.
OUTCOME:
All-cause mortality.
RESULTS:
Overall, 88% of patients were prescribed phosphate binders. Distributions of age, comorbid conditions, and other characteristics showed small differences between facilities with higher and lower percentages of phosphate binder prescription. Patient-level phosphate binder prescription was associated strongly at baseline with indicators of better nutrition, ie, higher values for serum creatinine, albumin, normalized protein catabolic rate, and body mass index and absence of cachectic appearance. Overall, patients prescribed phosphate binders had 25% lower mortality (HR, 0.75; 95% CI, 0.68-0.83) when adjusted for serum phosphorus level and other covariates; further adjustment for nutritional indicators attenuated this association (HR, 0.88; 95% CI, 0.80-0.97). However, this inverse association was observed for only patients with serum phosphorus levels ≥3.5 mg/dL. In the instrumental-variable analysis, case-mix-adjusted facility percentage of phosphate binder prescription (range, 23%-100%) was associated positively with better nutritional status and inversely with mortality (HR for 10% more phosphate binders, 0.93; 95% CI, 0.89-0.96). Further adjustment for nutritional indicators reduced this association to an HR of 0.95 (95% CI, 0.92-0.99).
LIMITATIONS:
Results were based on phosphate binder prescription; phosphate binder and nutritional data were cross-sectional; dietary restriction was not assessed; observational design limits causal inference due to possible residual confounding.
CONCLUSIONS:
Longer survival and better nutritional status were observed for maintenance HD patients prescribed phosphate binders and in facilities with a greater percentage of phosphate binder prescription. Understanding the mechanisms for explaining this effect and ruling out possible residual confounding require additional research.
AuthorsAntonio Alberto Lopes, Lin Tong, Jyothi Thumma, Yun Li, Douglas S Fuller, Hal Morgenstern, Jürgen Bommer, Peter G Kerr, Francesca Tentori, Takashi Akiba, Brenda W Gillespie, Bruce M Robinson, Friedrich K Port, Ronald L Pisoni
JournalAmerican journal of kidney diseases : the official journal of the National Kidney Foundation (Am J Kidney Dis) Vol. 60 Issue 1 Pg. 90-101 (Jul 2012) ISSN: 1523-6838 [Electronic] United States
PMID22385781 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Dialysis Solutions
  • Phosphates
Topics
  • Cohort Studies
  • Comorbidity
  • Dialysis Solutions (chemistry)
  • Female
  • Humans
  • Hyperphosphatemia (prevention & control)
  • Kidney Failure, Chronic (epidemiology, therapy)
  • Logistic Models
  • Middle Aged
  • Multicenter Studies as Topic
  • Nutritional Status
  • Phosphates (metabolism)
  • Practice Patterns, Physicians'
  • Renal Dialysis (adverse effects, mortality)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: